UFP Technologies (UFPT) Earnings Date & Reports

Key Takeaways

• UFP Technologies, Inc. (UFPT) is scheduled to report its third quarter 2026 results on Tuesday, November 3, 2026, after the market close, with a conference call on November 4 at 8:30 a.m. ET.
• Consensus estimates tracked by MarketBeat point to earnings per share (EPS) of $2.49 on revenue of roughly $166.89 million for the September 2026 quarter.
• The company enters the print after a record Q2 2026, when sales rose 15.1% to $174.0 million and adjusted EPS reached $2.92.
• Investors will focus on MedTech sales growth, gross margin trends, and progress reducing the backlog tied to the company's Illinois AJR facility.
• New robotic surgery program launches and the Dominican Republic expansion are key demand and execution themes heading into the report.
• For additional context on this ticker, explore the Major News, Today's Price Move, Price Targets, and Forecast pages.
• You can also discover related opportunities through Tickeron's Trending AI Robots.

Earnings Context and Why It Matters

UFP Technologies is a contract development and manufacturing organization specializing in single-use and single-patient medical devices, with the medical market representing the vast majority of its sales. Its quarterly results serve as a barometer for medical-device demand and for the company's ability to convert a growing pipeline into profitable output. The stock has experienced meaningful volatility around recent prints, and the prior quarter delivered record sales, net income, and EPS. Heading into this report, investors are weighing healthy MedTech demand against lingering operational inefficiencies and labor-related costs. How the company balances these forces will shape sentiment around its near-term earnings trajectory.

Earnings Expectations

For the third quarter of 2026, analysts expect UFP Technologies to deliver continued top-line expansion. Consensus estimates tracked by MarketBeat call for EPS of approximately $2.49 on revenue of about $166.89 million, which would represent year-over-year growth from the $154.6 million in sales reported in the third quarter of 2025. It is worth noting that estimates vary across data providers, so investors should treat these figures as directional rather than exact.

The company's recent history offers useful context. In Q2 2026, UFP Technologies reported record net sales of $174.0 million, up 15.1% year over year, with GAAP (Generally Accepted Accounting Principles) EPS of $2.68 and adjusted EPS of $2.92, beating consensus by a wide margin. In Q1 2026, sales were $154.2 million with adjusted EPS of $2.48. These strong recent beats raise the bar for the upcoming quarter, while also highlighting the company's capacity to outperform when operational execution improves.

Key metrics investors will scrutinize include organic sales growth, gross margin, and the pace of backlog reduction at the AJR facility, where labor-related disruptions previously delayed roughly $8 million in orders.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following earnings-driven names like UFP Technologies, the AI Screener offers a structured way to surface comparable opportunities across the medical-device and broader industrial landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the Q3 2026 report is cautiously constructive, supported by the company's record-setting second quarter but tempered by concerns over margin consistency and operational execution. The stock has traded well below its 52-week high in recent months, reflecting investor uncertainty about how quickly inefficiencies at the AJR facility will normalize and how ramp-up costs tied to new programs will flow through results. A strong prior-quarter beat has historically drawn attention to UFP Technologies, but the market will be watching closely for confirmation that demand strength is translating into sustained profitability rather than being absorbed by transitional costs.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should track several factors that will influence the company's trajectory in the quarters ahead.

First, watch the trajectory of gross margin. Management has indicated that efficiency-related headwinds should gradually improve, but that some inefficiencies could persist into the fourth quarter and early 2027 as the company prioritizes output over cost optimization. The pace of that recovery will be a central theme on the earnings call.

Second, monitor the company's new robotic surgery programs, which management expects to reach commercial production by year-end. These launches are positioned to generate meaningful revenue in 2026 and beyond, making execution timing an important catalyst.

Third, the Dominican Republic expansion continues to ramp, with the Santiago facility now in commercial production and additional programs in qualification. Progress here affects both capacity and longer-term margin structure.

Finally, pay attention to customer concentration and demand signals in the medical market, along with any commentary on the extension and expansion of the company's largest customer contract. These factors collectively frame the risk-and-reward picture following the upcoming report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations